These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1709682)

  • 1. Neutralizing antibody to Mengo virus, induced by synthetic peptides.
    Muir S; Weintraub JP; Hogle J; Bittle JL
    J Gen Virol; 1991 May; 72 ( Pt 5)():1087-92. PubMed ID: 1709682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Mengo virus T helper cell epitopes.
    Muir S; Kobasa D; Bittle J; Scraba D
    J Gen Virol; 1994 Nov; 75 ( Pt 11)():2925-36. PubMed ID: 7525861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T cell response to Mengo virus in mice: effector cell phenotype and target proteins.
    Escriou N; Leclerc C; Gerbard S; Giraud M; van der Werf S
    J Gen Virol; 1995 Aug; 76 ( Pt 8)():1999-2007. PubMed ID: 7636480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Mengo virus neutralization epitopes. II. Infection of mice with an attenuated virus.
    Kobasa D; Mulvey M; Lee JS; Scraba DG
    Virology; 1995 Dec; 214(1):118-27. PubMed ID: 8525606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies elicited by a biosynthetic peptide related to a major immunogenic area of FMDV A12.
    Borca MV; Moore DM; Srikumaran S; Morgan DO
    Viral Immunol; 1990; 3(2):147-60. PubMed ID: 1694429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological prospects for peptide vaccines against foot-and-mouth disease virus.
    Parry NR; Ouldridge EJ; Barnett PV; Clarke BE; Francis MJ; Fox JD; Rowlands DJ; Brown F
    J Gen Virol; 1989 Nov; 70 ( Pt 11)():2919-30. PubMed ID: 2479714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Mengo virus neutralization epitopes.
    Boege U; Kobasa D; Onodera S; Parks GD; Palmenberg AC; Scraba DG
    Virology; 1991 Mar; 181(1):1-13. PubMed ID: 1704653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mimicry of viral epitopes with retro-inverso peptides of increased stability.
    Benkirane N; Guichard G; Briand JP; Muller S; Brown F; Van Regenmortel MH
    Dev Biol Stand; 1996; 87():283-91. PubMed ID: 8854029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
    Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
    Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
    van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
    Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New virus-specific T-helper epitopes of foot-and-mouth disease viral VP1 protein.
    Volpina OM; Gelfanov VM; Yarov AV; Surovoy AYu ; Chepurkin AV; Ivanov VT
    FEBS Lett; 1993 Oct; 333(1-2):175-8. PubMed ID: 7693508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody formation in swine infected with seven strains of porcine reproductive and respiratory syndrome virus as measured by indirect ELISA with peptides containing the GP5 neutralization epitope.
    Plagemann PG
    Viral Immunol; 2006; 19(2):285-93. PubMed ID: 16817771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence.
    Barnett PV; Pullen L; Staple RF; Lee LJ; Butcher R; Parkinson D; Doel TR
    J Gen Virol; 1996 May; 77 ( Pt 5)():1011-8. PubMed ID: 8609466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
    Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
    Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactive and serotype-specific antibodies against foot-and-mouth disease virus generated by different regions of the same synthetic peptide.
    Doel TR; Doel CM; Staple RF; DiMarchi R
    J Virol; 1992 Apr; 66(4):2187-94. PubMed ID: 1372368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of retro-inverso peptides as synthetic vaccines.
    Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
    Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.
    Saikawa T; Anderson S; Momoeda M; Kajigaya S; Young NS
    J Virol; 1993 Jun; 67(6):3004-9. PubMed ID: 7684458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice.
    Zamorano P; Wigdorovitz A; Perez-Filgueira M; Carrillo C; Escribano JM; Sadir AM; Borca MV
    Virology; 1995 Oct; 212(2):614-21. PubMed ID: 7571431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides against foot-and-mouth disease--immunization with VP1-peptides of type O1-Kaufbeuren.
    Liebermann H; Holl U; Reimann I; Nöckler A; Schäfer D; Thalmann G; Dölling R
    Arch Exp Veterinarmed; 1990; 44(6):883-90. PubMed ID: 1966360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2.
    Hastings GZ; Speller SA; Francis MJ
    J Gen Virol; 1990 Dec; 71 ( Pt 12)():3055-9. PubMed ID: 1703215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.